At Genmab, we’re driven by the impact innovation can have on people living with cancer. During this #AntibodyHour 🕙, our colleague Emily Spencer, RN, Senior Manager, Patient Engagement Liaison, shares her hopes for how cancer care will evolve in the next 5 years. Learn more

This week we hosted our 4th annual Science Day, a day dedicated to fostering two-way dialogue between leaders from patient advocacy and professional organizations, as well as our patient advisors. The day brought together shared perspectives and a strong commitment to continue

Follow for more price errors 🚨 They go fast, just like this one... https://t.co/dbuEooegEz

Breaking #News: Genmab to acquire Merus, a clinical-stage #biotech, expanding our late-stage #oncology pipeline and accelerating sustainable growth. This proposed acquisition aligns with our long-term strategy and track record in antibody innovation and strengthens our

This #BloodCancerAwarenessMonth, we're inspired by Arlen, who shares his experience living with diffuse large B-cell lymphoma (#DLBCL). We hope his story of resilience empowers others navigating their health journeys. https://t.co/s5ZfuXZiRt

We’re focused on our commitment to our vision and strategic roadmap as we aim to innovate for the benefit of patients. At the heart of this journey are the patients. Their perspectives guide all we do at Genmab. We always want them to feel seen and heard. Hear from Daan Meester

From coast to coast, SERVPRO franchise professionals have the fleet, the team, and the tools to respond fast. 🚛

During this edition of Antibody Hour 🕙, hear from @stephanielieber of @ImermanAngels as she shares why peer-to-peer support is vital in cancer care. At Genmab, we’re inspired by voices like hers—reminding us that advancing science must go hand in hand with advancing patient

We’re excited to be presenting at this year’s @myESMO Congress and connect with experts in the field. To learn more about our pipeline of innovative antibodies, visit booth #55 and click here: https://t.co/oUmO5Aki7J. #Oncology #ESMO25

#ICYMI: Recently on #AntibodyHour 🕙: Our colleague Brian Elliott, VP, Clinical Lead and former oncologist shared his perspective on the innovation behind our antibody medicines and how at Genmab we are driven by a patient-first mindset and collaborative spirit. Watch below

Today, Genmab colleagues participated in Global Volunteer Day: volunteering over 3,000 hours for 43 local charities in the communities where we live and work. Learn more here: https://t.co/DjiTHQuRtu. #CommunityAtGenmab

Reinforcement Learning (RL) has long been the dominant method for fine-tuning, powering many state-of-the-art LLMs. Methods like PPO and GRPO explore in action space. But can we instead explore directly in parameter space? YES we can. We propose a scalable framework for

We’re attending the 13th Annual Meeting of the @SocietyofHemOnc #SOHO25 covering the latest advancements and innovation in the #hematology space. To learn more about our innovative antibody science and investigational therapies, visit our booth #176.

It’s #AntibodyHour! 🕙At Genmab, our culture is defined by genuine collaboration and a shared commitment to putting patients first. Hear more from our colleague Leslie Amendola on what drives us. #Innovation #culture

Breaking News: We shared new data evaluating one of our assets at the @SocietyofHemOnc Annual Meeting, in partnership with @Abbvie. #SOHO2025 Read more: https://t.co/UlNmB3sKTi

We’re looking forward to presenting 6 abstracts that showcase our latest research in #BloodCancer at the @SocietyofHemOnc Annual Meeting tomorrow. #SOHO2025

Be Satisfied

#NewsUpdate: The FDA has granted Breakthrough Therapy Designation for our investigational treatment in #GynecologicOncology. This designation underscores our commitment to advancing innovative antibody therapies for people with cancer and other serious diseases. Read more:

What’s the secret to staying inspired and focused as a leader? In this #AntibodyHour 🕙 episode, our CEO Jan van de Winkel, PhD shares how Genmab’s North Star—our belief in the power of antibodies to transform lives—drives everything we do. #Innovation #Biotech

As a socially responsible biotech company, we’re excited to launch the Genmab and Mercer County Community College Mentoring Program. Genmab mentors will work with science scholarship recipients for 10 months of growth, learning & connection. Investing in the next generation of

#ICYMI: At Genmab, transforming patient lives drives our 2030 vision. Hear from Ewan Robson, Senior Director, EU Medical Affairs, on how patient insights fuel our innovation and allow us to push boundaries in bringing medicines to patients. #PatientFirst #Innovation

Should hyper-scalers wave the white flag on custom chips? 🤯 On this week's "The Flip" segment, @PatrickMoorhead argues they should, citing high design costs and the critical need for immediate time-to-market with merchant GPUs. @DanielNewmanUV pushes back, asserting that

#ICYMI: What makes a difference in a cancer journey? Our patient advisors and patient advocates say: self-advocacy. This week on #AntibodyHour 🕙, hear from Keith, Portia Badham, and Stephanie Lieber on why it’s not just empowering—it’s essential. #PatientAdvocacy

Genmab is delivering strong H1 2025 results with 19% revenue growth and 56% operating profit increase. We’re accelerating our late-stage pipeline, maximizing potential of our commercial medicines, and executing disciplined capital allocation to drive continued growth and value

#InvestorUpdate: We announced our earnings report for the first half of 2025, highlighting robust revenue growth and progress in advancing key pipeline assets. Learn more and tune in to our investor call: https://t.co/vVU5SrNrIO. #Biotech #Earnings #AntibodyMedicines